N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
Star0
Identification
- Generic Name
- N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
- DrugBank Accession Number
- DB02855
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 385.4552
Monoisotopic: 385.221285739 - Chemical Formula
- C18H31N3O6
- Synonyms
- N-(3-Propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCathepsin B Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Cathepsin B, antagonists & inhibitors
- Cathepsin Inhibitors
- Central Nervous System Agents
- Compounds used in a research, industrial, or household setting
- Cysteine Proteinase Inhibitors
- Enzyme Inhibitors
- Neuroprotective Agents
- Oligopeptides
- Peptides
- Protease Inhibitors
- Protective Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- Isoleucine and derivatives / N-acyl-L-alpha-amino acids / Proline and derivatives / Alpha amino acid amides / N-acylpyrrolidines / Pyrrolidine carboxylic acids / N-acyl amines / Tertiary carboxylic acid amides / Secondary alcohols / Secondary carboxylic acid amides show 8 more
- Substituents
- Alcohol / Aliphatic heteromonocyclic compound / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-dipeptide / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid / Fatty acyl show 23 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 134448-10-5
- InChI Key
- UDNIFTKCMDIXFC-ABHRYQDASA-N
- InChI
- InChI=1S/C18H31N3O6/c1-4-8-19-16(24)13(22)10-14(23)20-15(11(3)5-2)17(25)21-9-6-7-12(21)18(26)27/h11-13,15,22H,4-10H2,1-3H3,(H,19,24)(H,20,23)(H,26,27)/t11-,12-,13-,15-/m0/s1
- IUPAC Name
- (2S)-1-[(2S,3S)-2-[(3S)-3-hydroxy-3-(propylcarbamoyl)propanamido]-3-methylpentanoyl]pyrrolidine-2-carboxylic acid
- SMILES
- [H][C@](O)(CC(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(O)=O)[C@@]([H])(C)CC)C(=O)NCCC
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5287408
- PubChem Substance
- 46507264
- ChemSpider
- 4449798
- ZINC
- ZINC000015894720
- PDBe Ligand
- 074
- PDB Entries
- 1qdq / 3hhi / 3qsd / 8t8n
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 8.23 mg/mL ALOGPS logP 0.09 ALOGPS logP -0.29 Chemaxon logS -1.7 ALOGPS pKa (Strongest Acidic) 3.86 Chemaxon pKa (Strongest Basic) -2.3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 136.04 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 96.75 m3·mol-1 Chemaxon Polarizability 40.28 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.5678 Blood Brain Barrier - 0.9544 Caco-2 permeable - 0.7898 P-glycoprotein substrate Substrate 0.7076 P-glycoprotein inhibitor I Non-inhibitor 0.5984 P-glycoprotein inhibitor II Non-inhibitor 0.7219 Renal organic cation transporter Non-inhibitor 0.9514 CYP450 2C9 substrate Non-substrate 0.8775 CYP450 2D6 substrate Non-substrate 0.7866 CYP450 3A4 substrate Non-substrate 0.5146 CYP450 1A2 substrate Non-inhibitor 0.9156 CYP450 2C9 inhibitor Non-inhibitor 0.9309 CYP450 2D6 inhibitor Non-inhibitor 0.9377 CYP450 2C19 inhibitor Non-inhibitor 0.8735 CYP450 3A4 inhibitor Non-inhibitor 0.9222 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9619 Ames test Non AMES toxic 0.8874 Carcinogenicity Non-carcinogens 0.8791 Biodegradation Not ready biodegradable 0.7085 Rat acute toxicity 2.5003 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9715 hERG inhibition (predictor II) Non-inhibitor 0.8615
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00kr-1359000000-377349a9921e5f5e1f2a Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-05o0-1719000000-779bb0cf6a6ff212a60f Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-016s-8955000000-679b626b769585e0afdf Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03dl-8933000000-2b32490eb249cc21c3b4 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00b9-9431000000-1c1971147bd16fa07a3a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-01tc-9612000000-92d820bcc0cf591d444f Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 200.62029 predictedDeepCCS 1.0 (2019) [M+H]+ 202.51581 predictedDeepCCS 1.0 (2019) [M+Na]+ 208.29454 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCathepsin B
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Proteoglycan binding
- Specific Function
- Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. Has also been implicated in tumor invasion and metastasis.
- Gene Name
- CTSB
- Uniprot ID
- P07858
- Uniprot Name
- Cathepsin B
- Molecular Weight
- 37821.35 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52